Compare PDLB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | OCGN |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 387.3M |
| IPO Year | 2021 | 2014 |
| Metric | PDLB | OCGN |
|---|---|---|
| Price | $16.65 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 63.2K | ★ 10.3M |
| Earning Date | 04-24-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 31.58 |
| EPS | ★ 1.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,980.89 |
| P/E Ratio | $13.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.88 | $0.57 |
| 52 Week High | $18.01 | $2.73 |
| Indicator | PDLB | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 50.70 |
| Support Level | $15.84 | $1.47 |
| Resistance Level | $17.29 | $2.73 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 65.77 | 33.33 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").